Short Interest in Spero Therapeutics Inc (NASDAQ:SPRO) Drops By 8.1%

Spero Therapeutics Inc (NASDAQ:SPRO) was the recipient of a large decline in short interest in the month of September. As of September 30th, there was short interest totalling 356,000 shares, a decline of 8.1% from the August 30th total of 387,400 shares. Approximately 3.1% of the shares of the company are short sold. Based on an average daily trading volume, of 40,400 shares, the days-to-cover ratio is currently 8.8 days.

Shares of Spero Therapeutics stock opened at $10.85 on Tuesday. The firm has a market capitalization of $197.94 million, a PE ratio of -4.17 and a beta of 2.09. The company has a debt-to-equity ratio of 0.04, a current ratio of 13.66 and a quick ratio of 13.66. The company’s fifty day moving average price is $10.81 and its two-hundred day moving average price is $11.26. Spero Therapeutics has a 52-week low of $5.52 and a 52-week high of $14.48.

Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.10). Spero Therapeutics had a negative net margin of 321.37% and a negative return on equity of 33.84%. The business had revenue of $2.16 million during the quarter, compared to the consensus estimate of $6.95 million. Analysts predict that Spero Therapeutics will post -2.93 earnings per share for the current fiscal year.

Several equities research analysts have issued reports on SPRO shares. Zacks Investment Research lowered shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, September 12th. Oppenheimer lowered their price target on shares of Spero Therapeutics from $30.00 to $20.00 in a report on Wednesday, October 2nd. TheStreet lowered shares of Spero Therapeutics from a “c-” rating to a “d+” rating in a report on Monday, July 29th. ValuEngine lowered shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, September 10th. Finally, Janney Montgomery Scott started coverage on shares of Spero Therapeutics in a report on Monday, September 9th. They issued a “buy” rating on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $19.20.

Several institutional investors and hedge funds have recently bought and sold shares of SPRO. Acadian Asset Management LLC bought a new stake in shares of Spero Therapeutics in the 2nd quarter worth about $25,000. Marshall Wace LLP bought a new stake in shares of Spero Therapeutics in the 1st quarter worth about $39,000. D.A. Davidson & CO. bought a new stake in shares of Spero Therapeutics in the 2nd quarter worth about $115,000. Wells Fargo & Company MN grew its holdings in shares of Spero Therapeutics by 187.9% in the 2nd quarter. Wells Fargo & Company MN now owns 13,660 shares of the company’s stock worth $157,000 after purchasing an additional 8,915 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Spero Therapeutics by 30.7% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 25,118 shares of the company’s stock worth $290,000 after purchasing an additional 5,895 shares during the last quarter. 50.97% of the stock is currently owned by institutional investors and hedge funds.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.

Featured Story: How does a security become overbought?

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.